1. Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver disease by Antonio Petrarca, Luigi Rigacci, Patrizio Caini, Stefano Colagrande, Paolo Romagnoli, Francesco Vizzutti, Umberto Arena, Carlo Giannini, Monica Monti, Paolo Montalto, Marco Matucci-Cerinic, Alberto Bosi, Giacomo Laffi, and Anna Linda Zignego Blood Volume 116(3):335-342 July 22, 2010 ©2010 by American Society of Hematology

2. Behavior of mean values of the main immunologic data of the 19 patients with MC before RTX therapy and at the end of follow-up (six months after therapy interruption). Antonio Petrarca et al. Blood 2010;116:335-342 ©2010 by American Society of Hematology

3. Pattern of HCV RNA, alanine aminotransferase, and CD19 mean values of the 19 patients with HCV-positive MC during the study. Antonio Petrarca et al. Blood 2010;116:335-342 ©2010 by American Society of Hematology

4. Modifications of pretreatment therapeutic measures and ascites severity in the 6 patients with MC and decompensated cirrhosis. Antonio Petrarca et al. Blood 2010;116:335-342 ©2010 by American Society of Hematology